{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:07:01Z","timestamp":1791234421827,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1955-2","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T11:02:54Z","timestamp":1563447774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sj\u00f6gren syndrome"],"prefix":"10.1186","volume":"21","author":[{"given":"Patrick","family":"Hargreaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Daoudlarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Theron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice A.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Manchester Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Tiaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Manigold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"1955_CR1","unstructured":"Patel R, Shahane A. The epidemiology of Sjogren\u2019s syndrome. Clin Epidemiol. 2014;6:247\u201355."},{"key":"1955_CR2","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjogren syndrome. Nat Rev Dis Prim. 2016;2:16047 Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27383445\n                    \n                  .","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"1955_CR3","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.4317\/medoral.20199","volume":"20","author":"P Wei","year":"2015","unstructured":"Wei P, Li C, Qiang L, He J, Li Z, Hua H. Role of salivary anti-SSA\/B antibodies for diagnosing primary Sj\u00f6gren\u2019s syndrome. Med Oral Patol Oral Cir Bucal. 2015;20(2):e156\u201360.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"1","key":"1955_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1955_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/jaut.1999.0289","volume":"13","author":"EC Kolkowski","year":"1999","unstructured":"Kolkowski EC, Reth P, Pelusa F, Bosch J, Pujol-Borrell R, Coll J, et al. Th1 predominance and perforin expression in minor salivary glands from patients with primary Sj\u00f6gren\u2019s syndrome. J Autoimmun. 1999;13(1):155\u201362.","journal-title":"J Autoimmun"},{"issue":"3","key":"1955_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1046\/j.1365-2249.2002.01869.x","volume":"128","author":"DI Mitsias","year":"2002","unstructured":"Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1\/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren\u2019s syndrome. Clin Exp Immunol. 2002;128(3):562\u20138.","journal-title":"Clin Exp Immunol"},{"key":"1955_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","volume":"63","author":"A Nezos","year":"2015","unstructured":"Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, et al. Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis. J Autoimmun. 2015;63:47\u201358.","journal-title":"J Autoimmun"},{"key":"1955_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clim.2018.04.009","volume":"192","author":"A Voigt","year":"2018","unstructured":"Voigt A, Bohn K, Sukumaran S, Stewart CM, Bhattacharya I, Nguyen CQ. Unique glandular ex-vivo Th1 and Th17 receptor motifs in Sj\u00f6gren\u2019s syndrome patients using single-cell analysis. Clin Immunol. 2018;192:58\u201367.","journal-title":"Clin Immunol"},{"issue":"12","key":"1955_CR9","first-page":"2340","volume":"24","author":"J Helsloot","year":"1997","unstructured":"Helsloot J, Sturgess A. T cell reactivity to Sj\u00f6gren\u2019s syndrome related antigen La(SSB). J Rheumatol. 1997;24(12):2340\u20137.","journal-title":"J Rheumatol"},{"issue":"9","key":"1955_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00011-012-0495-x","volume":"61","author":"U Schurigt","year":"2012","unstructured":"Schurigt U, Eilenstein R, Gajda M, Leipner C, Sevenich L, Reinheckel T, et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res. 2012;61(9):1021\u20139.","journal-title":"Inflamm Res"},{"issue":"10","key":"1955_CR11","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/rheumatology\/keu486","volume":"54","author":"T Weitoft","year":"2015","unstructured":"Weitoft T, Larsson A, Manivel VA, Lysholm J, Knight A, Ronnelid J. Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies. Rheumatology (Oxford). 2015;54(10):1923\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"1955_CR12","doi-asserted-by":"publisher","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","volume":"114","author":"JS Ainscough","year":"2017","unstructured":"Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36\u03b3. Proc Natl Acad Sci U S A. 2017;114(13):E2748\u201357.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1955_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/cei.12644","volume":"181","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, et al. Interleukin-36\u03b1 axis is modulated in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Exp Immunol. 2015;181(2):230\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1955_CR14","doi-asserted-by":"publisher","first-page":"11044","DOI":"10.1038\/s41598-018-29411-9","volume":"8","author":"MC Edman","year":"2018","unstructured":"Edman MC, Janga SR, Meng Z, Bechtold M, Chen AF, Kim C, et al. Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sj\u00f6gren\u2019s syndrome patients. Sci Rep. 2018;8(1):11044 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30038391\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"7","key":"1955_CR15","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/art.38633","volume":"66","author":"SF Hamm-Alvarez","year":"2014","unstructured":"Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, et al. Tear cathepsin S as a candidate biomarker for Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol (Hoboken). 2014;66(7):1872\u201381.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"3","key":"1955_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1172\/JCI0214682","volume":"110","author":"K Saegusa","year":"2002","unstructured":"Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002;110(3):361\u20139.","journal-title":"J Clin Invest"},{"key":"1955_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fimmu.2017.00806","volume":"8","author":"M Theron","year":"2017","unstructured":"Theron M, Bentley D, Nagel S, Manchester M, Gerg M, Schindler T, et al. Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of cathepsin S. Front Immunol. 2017;8:806.","journal-title":"Front Immunol"},{"issue":"1","key":"1955_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/1354750X.2018.1514656","volume":"24","author":"Srikanth R. Janga","year":"2018","unstructured":"Janga SR, Shah M, Ju Y, Meng Z, Edman MC, Hamm-Alvarez SF. Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjogren\u2019s Syndrome. Biomarkers. 2019;24(1):91\u2013102.","journal-title":"Biomarkers"},{"issue":"5","key":"1955_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1006\/jaut.1995.0051","volume":"8","author":"SA Kellermann","year":"1995","unstructured":"Kellermann SA, McCormick DJ, Freeman SL, Morris JC, Conti-Fine BM. TSH receptor sequences recognized by CD4+ T cells in Graves\u2019 disease patients and healthy controls. J Autoimmun. 1995;8(5):685\u201398 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8579724\n                    \n                  .","journal-title":"J Autoimmun"},{"issue":"4","key":"1955_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaut.2005.08.007","volume":"25","author":"NA Danke","year":"2005","unstructured":"Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun. 2005;25(4):303\u201311 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16249070\n                    \n                  .","journal-title":"J Autoimmun"},{"issue":"4","key":"1955_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.40768","volume":"71","author":"C Rims","year":"2019","unstructured":"Rims C, Uchtenhagen H, Kaplan MJ, Carmona-Rivera C, Carlucci P, Mikecz K, et al. Citrullinated aggrecan epitopes as targets of autoreactive CD4+ T cells in patients with rheumatoid arthritis. Arthritis Rheumatol (Hoboken). 2019;71(4):518\u201328 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30390384\n                    \n                  .","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"1955_CR22","first-page":"91","volume":"256","author":"ER Mackow","year":"2001","unstructured":"Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. Curr Top Microbiol Immunol. 2001;256:91\u2013115 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11217408\n                    \n                  . [cited 2013 Oct 13].","journal-title":"Curr Top Microbiol Immunol"},{"key":"1955_CR23","unstructured":"Baldini C, Gallo A, Perez P, Mosca M, Alevizos I, Bombardieri S. Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjogren\u2019s syndrome. Clin Exp Rheumatol. 2012;30(5):785\u201390. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23009763\n                    \n                  ."},{"key":"1955_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaut.2017.11.003","volume":"87","author":"GM Verstappen","year":"2018","unstructured":"Verstappen GM, Corneth OBJ, Bootsma H, Kroese FGM. Th17 cells in primary Sj\u00f6gren\u2019s syndrome: pathogenicity and plasticity. J Autoimmun. 2018;87:16\u201325.","journal-title":"J Autoimmun"},{"key":"1955_CR25","doi-asserted-by":"crossref","unstructured":"Rivi\u00e8re E, Tchitchek N, Nocturne G, Pascaud J, Boudaoud S, Thai A, Allaire N, Jagla B, Mingueneau M MX. RNA sequencing detection of gene dysregulation in B cells sorted from salivary gland tissue and from peripheral blood reveals new pathways involved in primary Sj\u00f6gren\u2019s syndrome pathophysiology [abstract]. Arthritis Rheumatol 2018;70 (suppl. Available from: \n                    https:\/\/acrabstracts.org\/abstract\/rna-sequencing-detection-of-gene-dysregulation-in-b-cells-sorted-from-salivary-gland-tissue-and-from-peripheral-blood-reveals-new-pathways-involved-in-primary-sjogrens-syndrome-pathophysiolog\/\n                    \n                  . Accessed Nov 27 2018.","DOI":"10.1136\/annrheumdis-2018-eular.3315"},{"key":"1955_CR26","unstructured":"Joachims ML, Leehan KM, Dozmorov M, Pan Z, Rasmussen A, Radfar L, Lewis DM, Stone DU, Grundahl K, Scofield RH, Lessard CJ, Wren J, Thompson LF, Sivils KL, Maier-Moore J FA. Sjogren\u2019s syndrome minor salivary gland CD4+ T cells associate with oral disease features and have a T follicular helper-like transcriptional profile [abstract]. Arthritis Rheumatol 2018;70 (suppl. Available from: \n                    https:\/\/acrabstracts.org\/abstract\/sjogrens-syndrome-minor-salivary-gland-cd4-t-cells-associate-with-oral-disease-features-and-have-a-t-follicular-helper-like-transcriptional-profile\/\n                    \n                  . Accessed Nov 27 2018."},{"issue":"1","key":"1955_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3899\/jrheum.160313","volume":"44","author":"GM Verstappen","year":"2017","unstructured":"Verstappen GM, Kroese FGM, Meiners PM, Corneth OB, Huitema MG, Haacke EA, et al. B cell depletion therapy normalizes circulating follicular Th cells in primary Sj\u00f6gren syndrome. J Rheumatol. 2017;44(1):49\u201358.","journal-title":"J Rheumatol"},{"issue":"9","key":"1955_CR28","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/art.40165","volume":"69","author":"GM Verstappen","year":"2017","unstructured":"Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, et al. Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol (Hoboken). 2017;69(9):1850\u201361.","journal-title":"Arthritis Rheumatol (Hoboken)."},{"key":"1955_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bcp.2017.10.001","volume":"146","author":"S Thanei","year":"2017","unstructured":"Thanei S, Theron M, Silva AP, Reis B, Branco L, Schirmbeck L, et al. Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages. Biochem Pharmacol. 2017;146:151\u201364.","journal-title":"Biochem Pharmacol"},{"key":"1955_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.0105-2896.2005.00310.x","volume":"207","author":"LC Hsing","year":"2005","unstructured":"Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev. 2005;207:229\u201341 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16181340\n                    \n                  .","journal-title":"Immunol Rev"},{"issue":"2","key":"1955_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1074-7613(00)80021-7","volume":"10","author":"TY Nakagawa","year":"1999","unstructured":"Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999;10(2):207\u201317 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10072073\n                    \n                  .","journal-title":"Immunity"},{"issue":"9","key":"1955_CR32","first-page":"RA290","volume":"11","author":"T Krakauer","year":"2005","unstructured":"Krakauer T. Chemotherapeutics targeting immune activation by staphylococcal superantigens. Med Sci Monit. 2005;11(9):RA290\u20135.","journal-title":"Med Sci Monit"},{"issue":"1","key":"1955_CR33","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1038\/s41598-017-01894-y","volume":"7","author":"M Tato","year":"2017","unstructured":"Tato M, Kumar SV, Liu Y, Mulay SR, Moll S, Popper B, et al. Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. Sci Rep. 2017;7(1):2775 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28584258\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"30","key":"1955_CR34","doi-asserted-by":"publisher","first-page":"29725","DOI":"10.18632\/oncotarget.5065","volume":"6","author":"RDA Wilkinson","year":"2015","unstructured":"Wilkinson RDA, Magorrian SM, Williams R, Young A, Small DM, Scott CJ, et al. CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner. Oncotarget. 2015;6(30):29725\u201339 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26358505\n                    \n                  .","journal-title":"Oncotarget"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1955-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:15:39Z","timestamp":1594941339000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1955-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1955"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1955-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients and healthy controls gave written consent upon enrolment. The protocol for specimen acquisition (26th of May 2014) was approved by the \u201cEthikkomission Nordwest- und Zentralschweiz\u201d under reference number EKNZ 2014-051.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All personal data of enrolled subjects were anonymised.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PH, MT, FK, MMY and BR are all current employees of Hoffmann-La Roche. At the time of the study, PH was employed by the Department of Rheumatology, University Hospital Basel, Switzerland. AT, BB, DK and TM declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}